

GSK delivers excellent Q2 with double digit sales growth



Specialty Medicines

£2.7bn +35%  
+13% excluding Covid

Vaccines

£1.7bn +3%  
+24% excluding Covid

General Medicines

£2.5bn +2%

Adjusted operating profit growth

7%

Adjusted EPS

34.7p +6%

Total EPS from continuing operations

17.5p -58%

Regulatory approvals

3

Targeted acquisitions

2

Dividend

16.25p

Journalists/media see press release on [www.gsk.com](http://www.gsk.com) for full details on Q2 2022.

Please read the cautionary statement regarding **forward-looking statements** and the definitions and reconciliations for non-IFRS measures on pages 68 to 69 of the press release. References to growth are at constant exchange rates (CER) unless stated otherwise.

Earnings per share have been adjusted to reflect the GSK Share Consolidation on 18 July 2022, see page 53 of the press release.

The amounts presented above for continuing operations and Adjusted results excludes the Consumer Healthcare business discontinued operation.

Affinivax acquisition is subject to customary closing conditions, including regulatory approval.